Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Consensus Statement

Management of Jaundice and Prevention of Severe Neonatal Hyperbilirubinemia in Infants ≥35 Weeks Gestation

Bhutani V.K.a, b · Maisels M.J.c · Stark A.R.d · Buonocore G.e

Author affiliations

aSchool of Medicine at Stanford University, Stanford, Calif., and bNewborn Pediatrics, Pennsylvania Hospital, Philadelphia, Pa., cDepartment of Pediatrics, William Beaumont Hospital, Royal Oak, Mich., dSection of Neonatology, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Tex., USA; eDepartment of Pediatrics, Obstetrics and Reproductive Medicine, Policlinico ‘Le Scotte’, University of Siena, Siena, Italy

Related Articles for ""

Neonatology 2008;94:63–67

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Consensus Statement

Published online: January 17, 2008
Issue release date: June 2008

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: https://www.karger.com/NEO

Abstract

Kernicterus is still occurring but should be largely preventable if health care personnel follow the recommendations listed in this guideline. These recommendations emphasize the importance of universal, systematic assessment of the risk of severe hyperbilirubinemia, lactation support, close follow-up, and prompt intervention when necessary. A systems-based approach to prevent severe neonatal hyperbilirubinemia should be implemented at all birthing facilities and coordinated with continuing ambulatory care. Translational research is needed to better understand the mechanisms of bilirubin neurotoxicity and potential therapeutic interventions.

© 2008 S. Karger AG, Basel


References

  1. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia: Maisels MJ, Baltz RD, Bhutani VK, Newman TB, Palmer H, Rosenfeld W, et al: Clinical practice guideline: management of hyperbilirubinemia in the newborn infant ≥35 weeks of gestation. Pediatrics 2004;114:297–316. http://www.aappolicy.aappublications.org/cgi/content/full/pediatrics;114/1/297.
  2. Ip S, Glicken S, Kulig J, Obrien R, Sege R, Lau J: Management of Neonatal Hyperbilirubinemia. Rockville, US Department of Health and Human Services, Agency for Healthcare Research and Quality. 03, E011. 2003. http://www.ahrq.gov/clinic/epcsums/neonatalsum.pdf.
  3. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Revised Guidance to Help Prevent Kernicterus. Sentinel Event Alert: Issue No. 31. August 31, 2004, pp 1–4. http://www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_31.htm.
  4. Bhutani VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR, Yeargin-Allsopp M: Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol 2004;24:650–662.
  5. Ebbesen F: Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr 2000;89:1213–1217.
  6. Manning DJ, Maxwell MJ, Todd PJ, Platt MJ: Prospective surveillance study of severe hyperbilirubinaemia in the newborn in the United Kingdom and Ireland. Arch Dis Child Fetal Neonatal Ed 2007;92:F342–346.
  7. Sgro M, Campbell D, Shah V: Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ 2006;175:587–590.
  8. Ostrow JD, Pascolo L, Shapiro SM, Tiribelli C: New concepts in bilirubin encephalopathy (review). Eur J Clin Invest 2003;33:988–997.
  9. Shapiro SM: Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND). J Perinatol 2005;25:54–59.
  10. Wennberg RP, Ahlfors CE, Bhutani VK, Johnson LH, Shapiro SM: Toward understanding kernicterus: a challenge to improve the management of jaundiced newborns. Pediatrics 2006;117:474–485.
  11. Ostrow JD, Pascolo L, Brites D, Tiribelli C: Molecular basis of bilirubin-induced neurotoxicity (invited review). Trends Mol Med 2004;10:65–70.
  12. Tiribelli C, Ostrow JD: The molecular basis of bilirubin encephalopathy and toxicity: report of an EASL Single Topic Conference, Trieste, Italy, 1–2 October, 2004. J Hepatol 2005;43:156–166.
  13. Watchko JF: Genetics and the risk of neonatal hyperbilirubinemia. Pediatr Res 2004;56:677–678.
  14. Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, Wu YW, Hudes ES, Escobar GJ; Jaundice and Infant Feeding Study Team: Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med 2006;354:1889–1900.
  15. Watchko JF: Vigintiphobia revisited. Pediatrics 2005;115:1747–1753.
  16. Newman TB, Xiong B, Gonzales VM, Escobar GJ: Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med 2000;154:1140–1147.
  17. Ebbesen F, Andersson C, Verder H, Grytter C, Pedersen-Bjergaard L, Petersen JR, Schaarup J: Extreme hyperbilirubinaemia in term and near-term infants in Denmark. Acta Paediatr 2005;94:59–64.
  18. Petersen JR, Okorodudu AO, Mohammad AA, Fernando A, Shattuck KE: Association of transcutaneous bilirubin testing in hospital with decreased readmission rate for hyperbilirubinemia. Clin Chem 2005;51:540–544.
  19. Stevenson DK, Wong RJ, Vreman HJ: Reduction in hospital readmission rates for hyperbilirubinemia is associated with use of transcutaneous bilirubin measurement. Clin Chem 2005;51:481–482.
  20. Maisels MJ, Kring E: Transcutaneous bilirubin levels in the first 96 h in a normal newborn population of ≥35 weeks’ gestation. Pediatrics 2006;117:1169–1173.
  21. Ho HT, Ng TK, Tsui KC, Lo YC: Evaluation of a new transcutaneous bilirubinometer in Chinese newborns. Arch Dis Child Fetal Neonatal Ed 2006;91:F434–F438.
  22. Bhutani VK, Johnson L: Kernicterus in late preterm infants cared for as term healthy infants. Semin Perinatol 2006;30:89–97.
  23. Huang MJ, Kua KE, Teng HC, Tang KS, Weng HW, Huang CS: Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004;56:682–689.
  24. Palmer RH, Keren R, Maisels MJ, Yeargin-Allsopp M: National Institute of Child Health and Human Development (NICHD) conference on kernicterus: a population perspective on prevention of kernicterus. J Perinatol 2004;24:723–725.
  25. Lannon C, Stark AR: Closing the gap between guidelines and practice: ensuring safe and healthy beginnings. Pediatrics 2004;114:494–496.
  26. Bhutani VK, Johnson LH, Schwoebel A, Gennaro S: A systems approach for neonatal hyperbilirubinemia in term and near-term newborns. J Obstet Gynecol Neonatal Nurs 2006;35:444–455.
  27. Eggert LD, Wiedmeier SE, Wilson J, Christensen RD: The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics 2006;117:e855–e862.
  28. Smitherman H, Stark AR, Bhutani VK: Early recognition of neonatal hyperbilirubinemia and its emergent management. Semin Fetal Neonatal Med 2006;11:214–224.
    External Resources
  29. Dollberg G, Mimouni M, Dollberg S: Computerized decision-making assistance for managing neonatal hyperbilirubinemia. Pediatrics 2006;117:262–263.
  30. Blackmon LR, Fanaroff AA, Raju TNK: Research on prevention of bilirubin-induced brain injury and kernicterus: National Institute of Child Health and Human Development Conference Executive Summary. Pediatrics 2004;114:229–233.
  31. Stevenson DK, Wong RJ, Vreman HJ, McDonagh AF, Maisels MJ, Lightner DA: NICHD Conference on Kernicterus: Research on Prevention of Bilirubin-Induced Brain Injury and Kernicterus: Bench-to-Bedside–Diagnostic Methods and Prevention and Treatment Strategies. J Perinatol 2004;24:521–525.
  32. Kaplan M, Hammerman C: Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol 2004;28:356–364.
  33. Kaplan M, Muraca M, Vreman HJ, Hammerman C, Vilei MT, Rubaltelli FF, Stevenson DK: Neonatal bilirubin production-conjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity. Arch Dis Child Fetal Neonatal Ed 2005;90:F123–F127.
  34. Gourley GR, Li Z, Kreamer BL, Kosorok MR: A controlled, randomized, double-blind trial of prophylaxis against jaundice among breastfed newborns. Pediatrics 2005;116:385–391.
  35. Newman TB, Liljestrand P, Escobar GJ: Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. Arch Pediatr Adolesc Med 2005;159:113–119.
  36. Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz JS: Identifying newborns at risk of significant hyperbilirubinaemia: a comparison of two recommended approaches. Arch Dis Child 2005;90:415–421.
  37. McDonagh AF: Ex uno plures: the concealed complexity of bilirubin species in neonatal blood samples. Pediatrics 2006;118:1185–1187.
  38. Roca L, Calligaris S, Wennberg RP, Ahlfors CE, Malik SG, Ostrow JD, Tiribelli C: Factors affecting the binding of bilirubin to serum albumins: validation and application of the peroxidase method. Pediatr Res 2006;60:724–728.
  39. Gordo AC, Falcao AS, Fernandes A, Brito MA, Silva RF, Brites D: Unconjugated bilirubin activates and damages microglia J Neurosci Res 2006;84:194–201.

Article / Publication Details

First-Page Preview
Abstract of Consensus Statement

Published online: January 17, 2008
Issue release date: June 2008

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 1661-7800 (Print)
eISSN: 1661-7819 (Online)

For additional information: https://www.karger.com/NEO


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.